Results 231 to 240 of about 556,334 (392)

Intravenous iRGD‐Guided, RBC‐Membrane Camouflaged Lactococcus Lactis Remodels Cold NSCLC and Enhances PD‐1 Blockade

open access: yesAdvanced Science, EarlyView.
This study presents an engineered probiotic platform, iRGD‐mRBC@FOLactis, combining red blood cell membrane cloaking and tumor‐penetrating peptide iRGD for enhanced PD‐1 blockade. The platform improves tumor targeting, immune cell activation and therapeutic efficacy in lung cancer, demonstrating significant promise in overcoming PD‐1/PD‐L1 therapy ...
Chen Chen   +9 more
wiley   +1 more source

Engineered Mesenchymal Stem Cell–NK Cell Complexes for Spatially Targeted and Functionally Revitalized Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
IL‐15‐engineered stem cell–NK cell complexes, assembled via bioorthogonal chemistry, enable effective lung cancer immunotherapy. Abstract Natural killer (NK) cells represent a powerful immunotherapeutic strategy due to their intrinsic cytotoxicity and ability to target tumor cells independently of antigen presentation.
Qian Zhang   +15 more
wiley   +1 more source

Uric Acid Functions as an Endogenous Modulator of Microglial Function and Amyloid Clearance in Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
Higher serum UA levels are associated with reduced AD risk in epidemiological studies. UA enhances microglial phagocytic capacity primarily by restoring CD36 and TREM2 receptor recycling that is impaired by Aβ exposure. Therapeutically, UA supplementation improves cognitive function and reduces neuropathology in AD mouse model by enhancing microglial ...
De Xie   +18 more
wiley   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

open access: yesAdvanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy